Biotech

All Articles

Lilly posts even more good data on its own regular insulin prospect

.On the heels of an FDA denial for its main rival Novo Nordisk, Eli Lilly is actually pushing on in ...

IN 8bio stops period 2 trial, gives up one-half of workforce

.Merely a couple of months after dosing the first patient in a stage 2 trial for newly identified gl...

Lilly, Haya ink $1B biobuck being overweight deal to look black genome

.Eli Lilly's search for excessive weight intendeds has actually led it to the darker genome. The Big...

ArsenalBio increases $325M, pivots away from previous lead property

.Arsenal Biosciences is actually going on up. The cell treatment business has added $325 million in ...

Lilly- supported effective weight loss biotech reports IPO

.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitte...

Aelis' marijuana usage medicine fails phase 2b, steering Indivior to re-think $100M possibility

.Aelis Farma's hopes of protecting a fast, good choice on a $100 thousand possibility remittance hav...

ProKidney halts stage 3 test certainly not needed to have for cell therapy permission

.ProKidney has stopped among a set of period 3 tests for its tissue treatment for renal illness afte...

Vaxcyte climbs on 'magnificent' 31-valent PCV win against Pfizer

.Vaxcyte introduced what analysts called "magnificent" period 1/2 data for its 31-valent pneumococca...

Recursion's brain health condition test presents little documentation of effectiveness

.Recursion has actually stumbled with a very early exam of its tech-enabled approach to drug explora...

Acepodia, Pfizer click together for chemistry-based cell therapy

.Contact it a case of good chemical make up: Acepodia, a biotech based on Nobel Champion science, is...